Alcon Inc. - Registered Shares

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prestige Brands Holdings

Among the medical sector, Alcon (ALC) and Prestige Consumer Healthcare (PBH) are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.

2 Intriguing Medical Stocks to Buy for Steady Growth as Earnings Approach

GENEVA--(BUSINESS WIRE)--Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health.

Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health

Alcon (ALC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Alcon (ALC) Might Surprise This Earnings Season

GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2024 Annual General Meeting.

Alcon Announces Results of 2024 Annual General Meeting

Edwards Lifesciences

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the better value opportunity right now?

ALC vs. EW: Which Stock Is the Better Value Option?

STAAR Surgical

STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).

Star Surgical Shines as U.S. Outlook Improves for 2024

GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2024 Annual General Meeting.

Alcon Publishes Agenda for 2024 Annual General Meeting

Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.

Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership

Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.

Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone

TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients.

Vivity, the World's Leading EDOF IOL, Reaches One Million Milestone

Alcon, Inc. (ALC) Q4 2023 Earnings Call Transcript

Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.

Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand

Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say

GENEVA--(BUSINESS WIRE)--Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023.

Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario

Beyond analysts' top -and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings

Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition

IDEXX Laboratories

Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Idexx Laboratories (IDXX). But which of these two stocks presents investors with the better value opportunity right now?

ALC or IDXX: Which Is the Better Value Stock Right Now?

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase

Alcon Inc. (NYSE:ALC ) Q3 2023 Earnings Call Transcript November 15, 2023 8:00 AM ET Company Participants Dan Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Veronika Dubajova - Citi Larry Biegelsen - Wells Fargo Daniel Buchta - ZKB Ryan Zimmerman - BTIG Anthony Petrone - Mizuho Group Jeff Johnson - Baird Graham Doyle - UBS Operator Greetings and welcome to the Alcon Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Alcon Inc. (ALC) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say

Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.

Alcon's stock falls as third-quarter sales miss estimates

GENEVA--(BUSINESS WIRE)--Alcon Reports Third Quarter 2023 Results.

Alcon Reports Third Quarter 2023 Results

Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.

News for Alcon Inc. - Registered Shares Stock (ALC)